Integrative Tumor Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA, USA.
Am J Hum Genet. 2024 Sep 5;111(9):1864-1876. doi: 10.1016/j.ajhg.2024.07.012. Epub 2024 Aug 12.
We performed a series of integrative analyses including transcriptome-wide association studies (TWASs) and proteome-wide association studies (PWASs) of renal cell carcinoma (RCC) to nominate and prioritize molecular targets for laboratory investigation. On the basis of a genome-wide association study (GWAS) of 29,020 affected individuals and 835,670 control individuals and prediction models trained in transcriptomic reference models, our TWAS across four kidney transcriptomes (GTEx kidney cortex, kidney tubules, TCGA-KIRC [The Cancer Genome Atlas kidney renal clear-cell carcinoma], and TCGA-KIRP [TCGA kidney renal papillary cell carcinoma]) identified 38 gene associations (false-discovery rate <5%) in at least two of four transcriptomic panels and identified 12 genes that were independent of GWAS susceptibility regions. Analyses combining TWAS associations across 48 tissues from GTEx identified associations that were replicable in tumor transcriptomes for 23 additional genes. Analyses by the two major histologic types (clear-cell RCC and papillary RCC) revealed subtype-specific associations, although at least three gene associations were common to both subtypes. PWAS identified 13 associated proteins, all mapping to GWAS-significant loci. TWAS-identified genes were enriched for active enhancer or promoter regions in RCC tumors and hypoxia-inducible factor binding sites in relevant cell lines. Using gene expression correlation, common cancers (breast and prostate) and RCC risk factors (e.g., hypertension and BMI) display genetic contributions shared with RCC. Our work identifies potential molecular targets for RCC susceptibility for downstream functional investigation.
我们进行了一系列综合分析,包括全转录组关联研究(TWAS)和全蛋白质组关联研究(PWAS),以提名和优先考虑实验室研究的分子靶标。基于对 29020 名受影响个体和 835670 名对照个体的全基因组关联研究(GWAS)以及在转录组参考模型中训练的预测模型,我们在四个肾脏转录组(GTEx 肾脏皮质、肾脏小管、TCGA-KIRC[癌症基因组图谱肾脏肾透明细胞癌]和 TCGA-KIRP[TCGA 肾脏肾乳头细胞癌])中进行了 TWAS,确定了至少在两个转录组面板中存在 38 个基因关联(错误发现率<5%),并确定了 12 个独立于 GWAS 易感性区域的基因。通过 GTEx 48 个组织的 TWAS 关联分析,确定了在肿瘤转录组中可复制的 23 个额外基因的关联。主要组织学类型(透明细胞肾细胞癌和乳头状肾细胞癌)的分析揭示了亚类型特异性关联,尽管至少有三个基因关联存在于两个亚类型中。PWAS 确定了 13 个相关蛋白,全部映射到 GWAS 显著位点。TWAS 鉴定的基因在 RCC 肿瘤中富含活跃的增强子或启动子区域,在相关细胞系中富含缺氧诱导因子结合位点。使用基因表达相关性,常见癌症(乳腺癌和前列腺癌)和 RCC 风险因素(如高血压和 BMI)显示与 RCC 共享的遗传贡献。我们的工作确定了 RCC 易感性的潜在分子靶标,以进行下游功能研究。